Iclal Halici1, Saziye Sezin Palabiyik2, Fatma Guducu-Tufekci1, Asli Ozbek-Bilgin3, Atilla Cayir4. 1. Department of Pediatric Nursing, Faculty of Health Science, Ataturk University, Erzurum, Turkey. 2. Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Ataturk University, Erzurum, Turkey. 3. Department of Pharmacology, Faculty of Medicine, Ataturk University, Erzurum, Turkey. 4. Department of Pediatric Endocrinology, Erzurum Regional Education and Research Hospital, Erzurum, Turkey.
Abstract
BACKGROUND: The aim of this study was to compare serum endothelial cell-specific molecule-1 (endocan) in pediatric patients with metabolic syndrome (MetS) and in healthy children, and to determine whether it can be used as an indicator of endothelium damage-induced complications in pediatric MetS patients. METHODS: The study included 30 patients, aged 6-16 years, who were diagnosed with MetS. Another 30 children with no diseases were recruited as healthy controls. Endocan concentration was measured using enzyme-linked immunosorbent assay. RESULTS: Endocan was increased almost threefold in the MetS group compared with the healthy group. Systolic arterial tension and diastolic arterial tension, serum triglyceride, total cholesterol, and low-density lipoprotein cholesterol were higher, and high-density lipoprotein cholesterol was lower, in the MetS children than in the healthy group. Fasting blood glucose (FBG), hemoglobin A1c (HBA1C), and homeostasis model assessment insulin resistance (HOMA-IR) were also significantly increased in the children with MetS compared with the healthy group. CONCLUSIONS: Serum endocan level in pediatric MetS patients could be an important indicator of cardiovascular risk in adulthood.
BACKGROUND: The aim of this study was to compare serum endothelial cell-specific molecule-1 (endocan) in pediatric patients with metabolic syndrome (MetS) and in healthy children, and to determine whether it can be used as an indicator of endothelium damage-induced complications in pediatric MetS patients. METHODS: The study included 30 patients, aged 6-16 years, who were diagnosed with MetS. Another 30 children with no diseases were recruited as healthy controls. Endocan concentration was measured using enzyme-linked immunosorbent assay. RESULTS:Endocan was increased almost threefold in the MetS group compared with the healthy group. Systolic arterial tension and diastolic arterial tension, serum triglyceride, total cholesterol, and low-density lipoprotein cholesterol were higher, and high-density lipoprotein cholesterol was lower, in the MetS children than in the healthy group. Fasting blood glucose (FBG), hemoglobin A1c (HBA1C), and homeostasis model assessment insulin resistance (HOMA-IR) were also significantly increased in the children with MetS compared with the healthy group. CONCLUSIONS: Serum endocan level in pediatric MetS patients could be an important indicator of cardiovascular risk in adulthood.